A5031535555- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- Breast Implant and Reconstruction
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Global Cancer Incidence and Screening
- Cancer Treatment and Pharmacology
- Nonmelanoma Skin Cancer Studies
- Cutaneous Melanoma Detection and Management
- Cancer Cells and Metastasis
- Advances in Oncology and Radiotherapy
- Advanced Breast Cancer Therapies
- Genomics and Rare Diseases
- Advanced Radiotherapy Techniques
- Genetic factors in colorectal cancer
- Economic and Financial Impacts of Cancer
- Immunotherapy and Immune Responses
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Optical Coherence Tomography Applications
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Lymphatic System and Diseases
Dallas Surgical Group
2016-2025
Targeted Medical Pharma (United States)
2018-2024
Invitae (United States)
2022-2023
Target (United States)
2017-2022
Dallas Nephrology Associates
2020
Cornell University
2007-2019
Massachusetts General Hospital
2019
Advanced Breast Care
2016-2019
Roper Hospital
2018
Good Samaritan Hospital
2018
Pilot studies indicate that probe-guided resection of radioactive sentinel nodes (the first receive drainage from tumors) can identify regional metastases in patients with breast cancer. To confirm this finding, we conducted a multicenter study the method as used by 11 surgeons variety practice settings.
<h3>Importance</h3> The results of the American College Surgeons Oncology Group Z0011 (ACOSOG Z0011) trial were first reported in 2005 with a median follow-up 6.3 years. Longer was necessary because majority patients had estrogen receptor–positive tumors that may recur later disease course (the ACOSOG is now part Alliance for Clinical Trials Oncology). <h3>Objective</h3> To determine whether 10-year overall survival sentinel lymph node metastases treated breast-conserving therapy and...
Sentinel-lymph-node biopsy is associated with increased melanoma-specific survival (i.e., until death from melanoma) among patients node-positive intermediate-thickness melanomas (1.2 to 3.5 mm). The value of completion lymph-node dissection for sentinel-node metastases not clear.
Sentinel lymph node dissection (SLND) has eliminated the need for axillary (ALND) in patients whose sentinel (SN) is tumor-free. However, completion ALND with tumor-involved SNs remains standard to achieve locoregional control. Few studies have examined outcome of who do not undergo positive SNs. We now report local and regional recurrence information from American College Surgeons Oncology Group Z0011 trial.American was a prospective trial examining survival SN metastases detected by H E,...
Abstract Purpose: The purpose of this study was to test the hypothesis that circulating tumor cells (CTCs) are present in patients many years after mastectomy without evidence disease and these CTCs shed from persisting with breast cancer dormancy. Experimental Design: We searched for 36 dormancy candidate 26 age-matched controls using stringent criteria cytomorphology, immunophenotype, aneusomy. Results: Thirteen candidates, 7 22 clinical disease, had CTCs, usually on more than one...
The American College of Surgeons Oncology Group trial Z0011 was a prospective, randomized, multicenter comparing overall survival between patients with positive sentinel lymph nodes (SLNs) who did and not undergo axillary node dissection (ALND). current study compares complications associated SLN (SLND) plus ALND, versus SLND alone.From May 1999 to December 2004, 891 were randomly assigned + ALND (n = 445) or alone 446). Information on wound infection, seroma, paresthesia, brachial plexus...
Amplification and overexpression of the HER-2 oncogene in breast cancer is felt to be stable over course disease concordant between primary tumor metastases. Therefore, patients with -negative tumors rarely will receive anti-Her-2 antibody (trastuzumab, Herceptin) therapy. A very sensitive blood test was used capture circulating cells (CTCs) evaluate their gene status by fluorescence situ hybridization. The corresponding CTCs 31 showed 97% agreement, no false positives. In 10 -positive...
The early results of the American College Surgeons Oncology Group (ACOSOG) Z0011 trial demonstrated no difference in locoregional recurrence for patients with positive sentinel lymph nodes (SLNs) randomized either to axillary node dissection (ALND) or (SLND) alone. We now report long-term results.ACOSOG prospectively examined overall survival SLN metastases undergoing breast-conserving therapy undergo ALND after SLND further specific treatment. Locoregional was evaluated and compared between...
Purpose An estimated 10% of breast and ovarian cancers result from hereditary causes. Current testing guidelines for germ line susceptibility genes in patients with carcinoma were developed to identify carriers BRCA1/ 2 variants have evolved the panel-testing era. We evaluated capability National Comprehensive Cancer Network (NCCN) cancer pathogenic expanded panel testing. Methods institutional review board–approved multicenter prospective registry was initiated 20 community academic sites...
Abstract The Sunbelt Melanoma Trial is an ongoing multicenter prospective randomized trial that involves 79 centers and over 3600 patients from across the United States Canada. This one of first large studies to incorporate molecular staging using reverse transcriptase polymerase chain reaction (RT‐PCR). While results related primary endpoints study are not yet available, several analyses have shed light on many aspects sentinel lymph node (SLN) biopsy melanoma prognostic factors. In...
To better understand the factors associated with well-established gender difference in survival for patients melanoma.Gender is an important factor cutaneous melanoma. Male have a worse outcome when compared females. The reasons this are poorly understood.This prospective multi-institutional study included aged 18 to 70 years melanomas > or =1.0 mm Breslow thickness. Wide excision and sentinel lymph node (SLN) biopsy was performed all patients. Clinicopathologic factors, including gender,...
We performed a phase I trial of FANG vaccine, an autologous tumor-based product incorporating plasmid encoding granulocyte-macrophage colony-stimulating factor (GMCSF) and novel bifunctional short hairpin RNAi (bi-shRNAi) targeting furin convertase, thereby downregulating endogenous immunosuppressive transforming growth factors (TGF) β1 β2. Patients with advanced cancer received up to 12 monthly intradermal injections vaccine (1 × 10(7) or 2.5 cells/ml injection). GMCSF, TGFβ1, TGFβ2,...
This report presents 3 years of data on treatment efficacy, cosmetic results, and toxicities for patients enrolled the American Society Breast Surgeons MammoSite (Cytyc, Bedford, Mass) Brachytherapy Registry Trial.A total 1440 (1449 cases) with early stage breast cancer who were undergoing breast-conserving therapy treated device to deliver accelerated partial irradiation (APBI) (34 Gy in 3.4 fractions). Of these, 1255 (87%) cases had invasive (IBC; median size = 10 mm), 194 (13%) ductal...
Multiple recent reports have documented significant variability of reoperation rates after initial lumpectomy for breast cancer. To address this issue, a multidisciplinary consensus conference was convened during the American Society Breast Surgeons 2015 annual meeting. The mission statement to "reduce national rate in patients undergoing conserving surgery cancer, without increasing mastectomy or adversely affecting cosmetic outcome, thereby improving value care." goal develop toolbox...
Overexpression of urokinase plasminogen activator system or HER-2 (erbB-2) in breast cancer is associated with a poor prognosis. overexpression caused by gene amplification. The anti-HER-2 antibody trastuzumab significantly improves clinical outcome for HER2-positive cancer. Drugs that target the uPA are early trials. aims this study were to determine whether receptor (uPAR) amplification occurs and analysis individual tumor cells (TCs) blood tissue can add information conventional...
Abstract BACKGROUND Eighty‐seven institutions participated in a Registry Trial that was designed to collect data on the clinical use of MammoSite™ breast brachytherapy catheter for delivering irradiation. Patient demographics, technical reproducibility, cosmesis, and early toxicity were evaluated. METHODS From May 4, 2002 through July 30, 2004, 1419 patients with Stage 0, I, or II carcinoma who undergoing breast‐conserving therapy enrolled trial. The device placed 1403 these patients. 1237...
To evaluate the prognostic significance of molecular staging using reverse transcriptase polymerase chain reaction (RT-PCR) in detecting occult melanoma cells sentinel lymph nodes (SLNs) and circulating bloodstream.In this multicenter study, eligibility criteria included patient age 18 to 71 years, invasive > or = 1.0 mm Breslow thickness, no clinical evidence metastasis. SLN biopsy wide excision primary tumor were performed. SLNs examined by serial-section histopathology S-100...
Patients with breast cancer metastasis to the sentinel lymph nodes (SLNs) generally undergo completion axillary node dissection (cALND), either concurrently SLN biopsy or at a second procedure. The impact of timing cALND on pathologic results and complications in these patients has not been examined.We examined outcomes from SLN-positive American College Surgeons Oncology Group (ACOSOG) trials Z0010 Z0011. Pathologic data included primary tumor characteristics, total number SLNs recovered,...